Fractyl Logo
Rejuva logo

Rejuva Gene Therapy Platform

Rejuva is preclinical and has yet to be assessed by regulatory agencies.

T2D PROGRESSION IS DRIVEN BY DECLINING PANCREATIC FUNCTION AND INSULIN PRODUCTION

PANCREATIC ISLETS

DISEASE PROGRESSION

Figures adapted from: 1. Chen et al. Mol Metab. 2017 6:943-957. 2. Biondi et al. Int J Mol Sci. 2022 23:5522

PANCREATIC GENE THERAPY (PGTx) TO IMPROVE ISLET FUNCTION

AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy

AAV-delivered glucagon-like peptide 1 receptor agonist (GLP1RA) gene therapy

REJUVA IS A MODULAR PHYSIOLOGIC GENE THERAPY WITH 3 KEY ELEMENTS

Leverage our proprietary system to enable local, low dose virus delivery directly to pancreas

Vectors with high transduction efficiency and limited systemic biodistribution

Durable alteration of metabolic hormone response in the islets with tissue-restricted transgenes

REJUVA DEVELOPMENT PIPELINE IN T2D AND OBESITY

1. Product candidates under out Rejuva gene therapy platform will undergo Phase 1, Phase 2 and Phase 3 clinical trials. IND = Investigational New Drug Application with FDA or comparable regulatory body; IDE = Investigational Device Exemption.